Drug Profile
KW 0
Alternative Names: KW-0Latest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatic fibrosis
Most Recent Events
- 15 Feb 2022 Discontinued - Phase-II for Hepatic fibrosis in China (Beijing Kawin Technology Share-Holding pipeline, February 2022)